Ganitumab
Ganitumab (pronounced: gah-ni-tu-mab) is a type of monoclonal antibody that is being studied in the treatment of certain types of cancer. It is a type of targeted therapy.
Pronunciation
The pronunciation of Ganitumab is "gah-ni-tu-mab".
Etymology
The name Ganitumab is derived from the Latin word 'Ganitus', meaning 'born' and 'mab', a common suffix for monoclonal antibodies.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Targeted therapy: A type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells.
- Cancer: A term for diseases in which abnormal cells divide without control and can invade nearby tissues.
Usage
Ganitumab is used in the treatment of certain types of cancer. It works by binding to a specific protein on the surface of cancer cells, which can slow or stop their growth.
Side Effects
Like all medications, Ganitumab can cause side effects. These can include nausea, fatigue, and skin rash.
See Also
External links
- Medical encyclopedia article on Ganitumab
- Wikipedia's article - Ganitumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski